RT Journal Article
SR Electronic
T1 Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.18.20172072
DO 10.1101/2020.08.18.20172072
A1 Liu, Anthony P.Y.
A1 Li, Bryan K.
A1 Pfaff, Elke
A1 Gudenas, Brian
A1 Vasiljevic, Alexandre
A1 Orr, Brent A.
A1 Dufour, Christelle
A1 Snuderl, Matija
A1 Karajannis, Matthias A.
A1 Rosenblum, Marc K.
A1 Hwang, Eugene I.
A1 Ng, Ho-Keung
A1 Hansford, Jordan R.
A1 Szathmari, Alexandru
A1 Faure-Conter, Cécile
A1 Merchant, Thomas E.
A1 von Hoff, Katja
A1 Mynarek, Martin
A1 Rutkowski, Stefan
A1 Sahm, Felix
A1 Hawkins, Cynthia
A1 Robinson, Giles W.
A1 Gajjar, Amar
A1 Pfister, Stefan M.
A1 Bouffet, Eric
A1 Northcott, Paul A.
A1 Jones, David T.W.
A1 Huang, Annie
YR 2020
UL http://medrxiv.org/content/early/2020/08/22/2020.08.18.20172072.abstract
AB Background Recent genomic studies have shed light on the biology and inter-tumoral heterogeneity underlying pineal parenchymal tumors, in particular pineoblastomas (PBs) and pineal parenchymal tumors of intermediate differentiation (PPTIDs). Previous reports, however, had modest sample sizes and lacked power to integrate molecular and clinical findings. The different proposed subgroup structures also highlighted a need to reach consensus on a robust and relevant classification system.Methods We performed a meta-analysis on 221 patients with molecularly characterized PBs and PPTIDs. DNA methylation profiles were analyzed through complementary bioinformatic approaches and molecular subgrouping was harmonized. Demographic, clinical and genomic features of patients and samples from these pineal tumor subgroups were annotated.Findings Four clinically and biologically relevant consensus PB subgroups were defined: PB-miRNA1 (n=96), PB-miRNA2 (n=23), PB-MYC/FOXR2 (n=34) and PB-RB1 (n=25); with PPTID (n=43) remaining as a molecularly distinct entity. Genomic and transcriptomic profiling allowed the characterization of oncogenic drivers for individual subgroups, specifically, alterations in the microRNA processing pathway in PB-miRNA1/2, MYC amplification and FOXR2 overexpression in PB-MYC/FOXR2, RB1 alteration in PB-RB1, and KBTBD4 insertion in PPTID. Age at diagnosis, sex predilection and metastatic status varied significantly among tumor subgroups. While patients with PB-miRNA2 and PPTID had superior outcome, survival was intermediate for patients with PB-miRNA1, and dismal for those with PB-MYC/FOXR2 and PB-RB1.Interpretation We systematically interrogated the clinical and molecular heterogeneity within pineal parenchymal tumors and proposed a consensus nomenclature for disease subgroups, laying the groundwork for future studies as well as routine use in tumor classification.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was provided by American Lebanese Syrian Associated Charities, National Cancer Institute Cancer Center Grant (P30 CA021765) to St. Jude Childrens Research Hospital, National Cancer Institute Cancer Center Grant (P30 CA008748) to Memorial Sloan Kettering Cancer Center, the German Childhood Cancer Foundation (DKS 2015.01; Molecular Neuropathology 2.0 - Increasing diagnostic accuracy in paediatric neurooncology), the GPOH HIT-MED trial group, Canada Research Chair Award, Canadian Institute of Health Research, and Canadian Cancer Society Research Institute Grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Clinical data and tumor material, including those for the six previously unreported patients, were obtained according to Institutional Review Board approval from St. Jude Children's Research Hospital, Hospital for Sick Children, and contributing sites to German Cancer Research Center.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenomic data will be available from the authors upon reasonable request.